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Feature Endeavour Vol.33 No.4In present-day pharmacology and medicine, it is usually
taken for granted that cells contain a host of highly
specific receptors. These are defined as proteins on or
within the cell that bind with specificity to particular
drugs, chemicalmessenger substances or hormones and
mediate their effects on the body. However, it is only
relatively recently that the notion of drug-specific recep-
tors has become widely accepted, with considerable
doubts being expressed about their existence as late
as the 1960s. When did the receptor concept emerge,
how did it evolve and why did it take so long to become
established?
‘A beautiful but remote lady’
Tomost of the modern pharmacologists the receptor is
like a beautiful but remote lady. He has written her
many a letter and quite often she has answered the
letters. From these answers the pharmacologist has
built himself an image of this fair lady. He cannot,
however, truly claim ever to have seen her, although
one day he may do so [1].
SowroteDutchpharmacologistD.K. deJonghas recently
as 1964.Forhimand others, the cell receptorwas something
of an enigma. Not least, there was the problem of under-
standing how cells seemed to boast receptors for manmade
chemical substances synthesized in the laboratory. ForGer-
manprofessor of pharmacologyKlaus So¨hring speaking at a
colloquium in Hamburg in the early 1950s, this conundrum
was so great that it all but ruled out the existence of such
specific receptors. After all, he argued, how could God, the
Creator, have known which different kinds of pharmaceu-
tical substances would be developed by mankind [2].
Such doubts about receptors were only dispelled with
the development of the first receptor-specific remedies, in
particular the beta-receptor blockers for the therapy of
hypertension and the histamine-H2-receptor blockers for
the treatment of stomach ulcers. James Black, who was the
originator of both these groups of drugs, was awarded the
Nobel Prize for Medicine or Physiology in 1988 [3]. By this
time other researchers had elucidated the protein structure
and genetic basis of various other receptors and had even
visualised some of themwith electronmicroscopy. It became
increasingly clear that the human body contained many
hundreds of receptor subtypes, openingupavastnewfieldof*Tel.: +44 191 334 6557; fax: +44 191 334 6551.
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target these receptors for the specific treatment of various
diseases, ranging from cystic fibrosis to epilepsy [4].
Given the ubiquity of receptors in today’s biomedical
sciences, it is worth looking into the history of these
molecules in more detail. In particular, where did the
concept of a receptor come from, whywas concrete evidence
for its existence so long in coming and what role did the
notions of substance binding and of specific effects of sub-
stances play in this process?
Early thinking
The specificity of certain drugs to particular diseases had
been highlighted at least since the seventeenth century.
Perhaps the best-known example is the efficacy of Peru-
vian bark, the predecessor of quinine, in the treatment of
intermittent fevers or malaria (Figure 1) [5]. Yet, such
specificity remained a mysterious phenomenon. As one
sceptical author put it in 1797:
. . . as to specifics, if their idea be explicable by suppos-
ing an admiral sent down channel, across the Bay of
Biscay, and up to the Mediterranean, with express
orders to attack the Maltese, but with the strictest
charge not tomolest any other state whatever; I cannot
conceive any medicine such a specific as to conform
most punctually with such orders, to act vigorously
against one particular gland or humour of the
body, without in the least affecting or disturbing
any other . . . [6].
In theRomantic period, it becamemore commonplace to
encounter discussions of specificity. Writers like the Ger-
man Friedrich Sobernheim (1803–1846), for example,
began to use the physico-chemical concept of elective
affinities to rationalize the predilection of certain sub-
stances, including the newly isolated alkaloids, to affect
particular parts of the body. For Sobernheim, strychnine
had a specific affinity to the spinal cord, digitalis and
tobacco to the nerves of the heart, alcohol to the brain,
mercury to the salivary glands, ergot to the nerves of the
uterus, and sulphur to the skin [7]. Moreover, the English
physician James Blake (1814–1893) demonstrated in the
1840s that solutions of inorganic compounds with the
same macroscopic crystalline structure produced similar
physiological effects when infused intravenously into
animals. This led to further research on the relationship
between the chemical structure and pharmacological
effect of substances such as salts and the substitution
products of various alkaloids [8].j.endeavour.2009.09.001
Figure 1. Peruvian bark tree. Engraving by J. Howkins. Wellcome Library, London.
Figure 2. Paul Ehrlich in his study. Reproduced from de Kruif, P. (1927)
Mikrobenja¨ger. Orell Fu¨ssli, Zu¨rich.
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troversy had developed over whether pharmacological
action depended directly on the chemical structure of a
substance or rather upon its physical properties [9]. As we
shall see, this general problem formed an important back-
ground to the subsequent debate about the existence and
relevance of receptors.
Side-chains and receptive substances
The role of Paul Ehrlich (1854–1915) in the development of
the receptor concept is quite well-known [10], and I will
therefore only briefly sketch it here (Figure 2). Ehrlich’s
side-chain-theory formed an important basis for his work
on blood cells and on chemotherapy of infectious diseases
such as sleeping-sickness and syphilis. In 1910, his
research led to the introduction of Salvarsan, the famous
‘magic bullet’ against the germs of syphilis. Ehrlich’s side-
chain-theory was developed in the course of his studies into
the staining of body cells and tissues, into the oxygen
consumption of cells, and especially on the interaction
between bacterial toxins and the so-called anti-toxins or
antibodies formed by the body. In 1897 Ehrlich published
for the first time a full account of his side-chain-theory of
anti-toxin formation. The large ‘molecule’ of the cell pro-
toplasm was supposed to have certain side-chains that
were able to bind chemically the toxins produced by thewww.sciencedirect.combacteria. The thus occupied side-chains became unable to
fulfil their usual functions in nutrition and oxygen con-
sumption, forcing the cell to produce more side-chains. A
surplus of side-chains was released into the blood stream
where they bound as anti-toxins or antibodies to the bac-
terial toxins—forming thus the basis of immunity
Figure 3. Diagrams illustrating Paul Ehrlich’s side-chain theory. Wellcome Library, London.
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Seitenkette) with the term Receptor [11].
However, Ehrlich initially believed that receptors
existed only for toxins and for physiological foodstuffs
and ferments. Drugs and medicines could quite easily be
washed out of body tissues with solvents, so that he did
not assume that they were fixed to specific components of
the cell. He changed his mind only in 1907 [12], partly due
to results of his own further research, but in particular
also because of a different kind of receptor theory that
had been proposed by the Cambridge physiologist John
Newport Langley (1852–1925) (Figure 4). Langley’s con-
cept is particularly interesting because it placed specialwww.sciencedirect.comimportance on the notion of substance and of substance
binding.
In the mid-1870s, as a student of Michael Foster (1836–
1907), Langley had been given the task of studying the
effects of the plant drug jaborandi in animals, in particular
its effect on the heart. Foster was interested in whether the
automatic activity of the heart originated from its own
muscle fibres or from nerves leading to the heart. Langley
showed that the effect of jaborandi – a slowing down of the
heart beats – occurred when the heart nerves were paral-
yzed using curare. He also demonstrated that the effect of
jaborandi could be reversed by dripping a solution of
atropine directly on the exposed animal heart. Both these
Figure 4. John Newport Langley. Photogravure. Wellcome Library, London.
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the heart muscle and, to a certain extent, supported Fos-
ter’s view that the automatic heart beat probably origi-
nated from within the heart muscle itself [13].
This led Langley to pursue two lines of research that
were also of interest to other physiologists of the time: one
was the question whether pharmacological substances act
directly on the body tissues or indirectly by affecting the
endings of nerves leading into these tissues; the other was
the question how antagonistic action between drugs, for
example the one Langley had shown between jaborandi
and atropine, came about. In a further series of exper-
iments, he demonstrated the antagonism between pilocar-
pine (an alkaloid of jaborandi) and atropine on salivary
secretion in dogs and cats; pilocarpine stimulated
secretion, atropine stopped it, a new dose of pilocarpine
got it going again, a further dose of atropine stopped it, and
so on. How could this be explained? Obviously the relative
concentration of the two substances in the animal body
played a role, and both substances had to have a chemical
affinity to the relevant tissues. In 1878 Langley formulated
the following hypothesis:
. . . we may, I think, without much rashness, assume
that there is some substance or substances in the nerve
endings or gland cells with which atropin and pilo-
carpin are capable of forming compounds. On thiswww.sciencedirect.comassumption then the atropin or pilocarpin compounds
are formed according to some law of which their
relative mass and chemical affinity for the substances
are factors. In the analogous case with inorganic
substances, other things being equal, these are the
sole factors. To take the simplest case, if a and b
are both able to form, with y, the compounds ay,
by, then ay and by are both formed, quantity of ay
and by depending on the relative masses of a and b
present and their relative chemical affinity to y [14].
In other words, Langley used the analogy between two
inorganic chemical substances competing for reaction with
the same third inorganic substance as a model to explain
antagonistic drug action in the body. This implied that the
relevant body cells contained some specific substances to
which the drug substances had a chemical affinity. This
thought, as we shall see, formed the basis of his later
receptor concept.
Langley formulated his receptor concept only about 30
years later, because his research path led him into other
areas, in particular into the physiology of the autonomic
nervous system, a field in which he became an inter-
national authority. However, his neurophysiological
research led him eventually back to the question of drug
antagonisms.
The key experiment for his receptor concept involved
the antagonism between nicotine and curare and was
carried out on an anaesthetized rooster. Injection of nic-
otine led to a characteristic contraction of certain muscles
of the leg, recognizable in the stiff, extended legs of the
animal. This effect could be antagonised by injecting cur-
are, resulting in the relaxation of the leg muscles. This
antagonism could also be shown if the relevant nerves of
the leg muscles had been cut through and allowed to
degenerate, which meant for Langley that the two drugs
acted on the muscle tissue directly. Just like pilocarpine
and atropine, nicotine and curare competed for the same
substances in the protoplasm of the cells. Moreover, after
application of curare the relaxed legmuscles could bemade
to contract by applying an electric current. Langley con-
cluded from this finding that neither the drugs nor the
electric stimulus acted directly on the contractile sub-
stance of the muscle cells, but on what he called ‘accessory
substances’. And, he continued, ‘Since this accessory sub-
stance is the recipient of stimuli which it transfers to the
contractile material, we may speak of it as the receptive
substance of the muscle [15]’.
This statement, made in 1905, was the first clear for-
mulation of Langley’s receptor concept. He was very quick
to generalize it, suggesting that it could be applied to
explain also the action of other alkaloids, such as pilocar-
pine, atropine and strychnine, and of hormones, such as
adrenalin, secretin, thyroidin and the sex hormones. And
he wrote in general terms:
So we may suppose that in all cells two constituents
at least are to be distinguished, a chief substance,
which is concerned with the chief function of the cell
as contraction and secretion, and receptive sub-
stances which are acted upon by chemical bodies
and in certain cases by nervous stimuli. The receptive
138 Feature Endeavour Vol.33 No.4substance affects or is capable of affecting the metab-
olism of the chief substance [16].
Langley was aware of the similarity between his concept
of receptive substances in cells and Paul Ehrlich’s side-
chain theory. However, he maintained that they had
uncovered somewhat different phenomena. Both assumed,
as he put it, ‘atom-groups of the protoplasm’ of the cell, to
which substances could bind. But while Ehrlich’s side-
chains were ‘fundamental’ to the cell’s life (i.e. the cell
would die if they were all occupied by poisons), Langley’s
‘receptive substance’ merely modified the cell’s function
when a drug or hormone bound to it. Significantly, Langley
never adopted Ehrlich’s more general term ‘receptor’, but
stuck to his own term ‘receptive substances’ throughout his
life. Ehrlich, on the other hand, conceded that the receptor
concept was also applicable to drugs and medicines, not
only to toxins or foodstuffs.
The potential-poison theory
BothEhrlich and Langley had conceptualised the ‘receptor’
through analogy with chemical binding of substances, and
their theories were viewed as ‘chemical’ in nature. This,
however, meant that their theories got caught up in the
controversy over whether pharmacological substances
acted primarily through their chemical or their physical
properties. The great competitor to the receptor concepts of
Ehrlich and Langley was the so-called ‘potential-poison’
theory of the German pharmacologist Walther Straub
(1874–1944).
Straub had developed it during a research stay at the
Stazione Zoologica in Naples at the start of the new
century. There, he studied the antagonism between atro-
pine and the poison of the fly agaric, muscarine, on the
heart of the sea snail (Aplysia) and the torpedo fish. In
essence, he argued that a poison acted as long as there was
a concentration difference or ‘potential’ between the out-
side and the inside of the cell. The effect was due to a
deformation or other physical disturbance of the cell mem-
brane when the poison molecules penetrated it. Like Lang-
ley, Straub was quick to generalize, suggesting that his
physical theory of drug action applied also to other alka-
loids, such as pilocarpine, physostigmine and nicotine, and
to the hormone adrenalin [17]. Straub’s theory found sig-
nificant supporters in Britain, in particular Henry Dale
(1875–1968) and George Barger (1878–1939) of the Well-
come Physiological Research Laboratories and Arthur
Cushny (1866–1926), who held the chair in pharmacology
at University College London [18].
Straub offered a direct challenge to Ehrlich’s theory of
so-called chemoreceptors. At the annual assembly of Ger-
man naturalists and doctors in 1912, Straub pointed out
that there were many pharmacologically active substances
(such as nitrous oxide, carbonic acids and kali salts) whose
constitution made it very unlikely that they were capable
of reacting chemically within the organism. Theremight be
receptors for certain poisons, he conceded, but to build a
whole theory of chemoreceptors on this was impermissible
[19].
Moreover, it seems that Straub did not fully accept
Langley’s work as a contribution to the field of pharma-www.sciencedirect.comcology. As late as 1938, Straub addressed the International
Congress of Physiologists in Zurich with the following
statement:
. . . I may perhaps remind you that there are two types
of pharmacologist: those who study the living organ-
ism with a chemical substance, for example Claude
Bernard with curare or Langley with nicotine, and
such who use a living organism to study a chemical
substance; the former practise physiology, the latter
pharmacology [20]!
A receptive audience
However, the interwar period had also brought two import-
ant supporters of Langley’s theory of receptive substances
and of receptor theory more generally on the scene. Alfred
Joseph Clark (1885–1941), who succeeded Cushny in the
chair at UCL in 1920 and again, after Cushny’s death in
1926, in the Edinburgh chair of Materia Medica; and John
Henry Gaddum (1900–1965), who became professor of
pharmacology at UCL in 1935. Both Clark and Gaddum
had been students of Langley in Cambridge.
Based on quantitative dose-effect studies with the
transmitter substance acetylcholine, Clark suggested the
so-called receptor occupancy theory. According to this
theory the intensity of the pharmacological effect of a
substance was directly proportional to the number of cell
receptors occupied by the substance [21]. Gaddum, work-
ing on the dose-effect relations of adrenalin and ergota-
mine elucidated the competitive antagonism between two
substances at receptors and introduced the notion of re-
ceptor blockage by the antagonistic substance [22]. Clark
publicly attacked Straub over his physical potential-poison
theory, saying at a meeting of the Royal Society in London
in 1936 that it assumed processes that were unknown in
physical chemistry [23].
Despite such support and development of the receptor
concept, the critics remained vocal. Important was the
position of Sir Henry Dale, who was awarded the Nobel
Prize for his neurotransmitter research in 1936. Dale was
much more interested in the transmitter substances in the
nervous system than in their potential receptors. As late as
1943, at a conference of the Faraday Society in London, he
called the worth of the receptor concept for explaining
specific drug action into question:
It is a mere statement of fact to say that the action of
adrenaline picks out certain such effector-cells and
leaves others unaffected; it is a simple deduction that
the affected cells have a special affinity of some kind
for adrenaline; but I doubt whether the attribution to
such cells of ‘‘adrenaline-receptors’’ does more than re-
state this deduction in another form [24].
When, 5 years later, the American pharmacologist Ray-
mondP. Ahlquist (1914–1983) proposed the existence of two
types of adrenaline-receptors, alpha and beta, mediating
different patterns of pharmacological action, his paper on
this topic was rejected by the Journal of Pharmacology and
Experimental Therapeutics. Through personal contacts
with the editor of the American Journal of Physiology he
eventually managed to get it published [25]. Ironically,
Feature Endeavour Vol.33 No.4 139Ahlquist’s distinction between the two types of adrenaline-
receptors became the basis for the development of the first
therapeutically useful receptor blocking drug, the beta-
blocker propranolol, which was introduced by (Sir) James
Black in 1965. Only then did most pharmacologists start to
believe that receptors weremore than hypothetical entities,
or as de Jonghhad called them, ‘beautiful but remote ladies’.
Conclusion
The concept of ‘receptive substances’ or ‘receptors’ arose
from older notions of specific drugs and of elective affinities
in the late nineteenth and early twentieth centuries within
two different contexts: in immunology (with Paul Ehrlich)
and in neurophysiology (with John Newport Langley). Both
used the analogy of chemical binding between substances to
explain the biological phenomena they studied. This chemi-
cal analogy implied the existence of specific substances or
molecules in body cells that fixed biologically active sub-
stances, such as plant alkaloids, bacterial toxins, hormones
and transmitter substances. The chemical character of the
receptor concept led to controversy with thosewho favoured
physical explanations of drug action. This conflict continued
in the light of merely indirect evidence for about 60 years
until the receptor concept led to tangible therapeutic con-
sequences and receptors began to be identified with specific
proteins embedded in cell membranes or inside the cells.
The multitude of receptors that is now thought to exist
provides a great challenge but also significant opportunities
for the development of new specific treatments.
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